Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Fulcrum Therapeutics, Inc. - Common Stock
(NQ:
FULC
)
3.740
+0.030 (+0.81%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 14, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Fulcrum Therapeutics, Inc. - Common Stock
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
12 Health Care Stocks Moving In Friday's Intraday Session
↗
February 24, 2023
Via
Benzinga
Nasdaq Tumbles 2%; Timber Pharmaceuticals Shares Spike Higher
↗
February 24, 2023
U.S. stocks traded lower midway through trading, with the Dow Jones dropping over 450 points on Friday. The Dow traded down 1.39% to 32,692.94 while the NASDAQ fell 2.14% to 11,342.36. The S&P 500 also...
Via
Benzinga
FDA Slams Break On Fulcrum Therapeutics' Sickle Cell Disease Study, Shares Plummet
↗
February 24, 2023
Via
Benzinga
Fulcrum Therapeutics (FULC) Stock Plummets 55% on Clinical Hold News
↗
February 24, 2023
FULC stock is falling fast today due to a regulatory issue, but Fulcrum Therapeutics remains committed to combating sickle cell disease.
Via
InvestorPlace
US Stocks Open Lower; Dow Drops 1%
↗
February 24, 2023
U.S. stocks traded lower this morning, with the Dow Jones dropping over 150 points on Friday. Following the market opening Friday, the Dow traded down 1.05% to 32,807.33 while the NASDAQ fell 1.52% to...
Via
Benzinga
Expert Ratings for Fulcrum Therapeutics
↗
January 19, 2023
Via
Benzinga
Why Fulcrum Therapeutics Shares Are Falling
↗
January 18, 2023
Fulcrum Therapeutics Inc (NASDAQ: FULC) shares are trading lower by 6.43% to $13.09 Wednesday morning after the company announced pricing of an upsized public offering of common stock.
Via
Benzinga
Looking Into Fulcrum Therapeutics's Return On Capital Employed
↗
December 06, 2022
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
February 24, 2023
Via
Benzinga
Fulcrum Therapeutics Announces Clinical Hold on FTX-6058 in Sickle Cell Disease
February 24, 2023
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 10, 2023
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics to Participate at the Upcoming SVB Securities Global Biopharma Conference
February 08, 2023
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
$30M Bet On Deciphera Pharmaceuticals? Check Out These 4 Stocks Insiders Are Buying
↗
January 25, 2023
Although US stocks closed mixed on Tuesday, there were a few notable insider trades.
Via
Benzinga
The Week In Charts - Becoming A Successful Trader
↗
January 21, 2023
Dave discusses various topics, including intra-day trading and trading opening gap reversals, the current stock market conditions, and his two cents on your favorite stock picks.
Via
Talk Markets
Fulcrum Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
January 17, 2023
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
↗
January 17, 2023
Via
Benzinga
Fulcrum Therapeutics Announces Proposed Public Offering of Common Stock
January 17, 2023
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
January 16, 2023
Via
Benzinga
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 13, 2023
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
$3.4 Million Bet On CrowdStrike Holdings? Check Out These 3 Stocks Insiders Are Buying
↗
January 09, 2023
Although US stocks closed sharply higher on Friday, there were a few notable insider trades.
Via
Benzinga
Fulcrum Therapeutics Provides Business Update and 2023 Outlook
January 04, 2023
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Announces CEO Transition
January 04, 2023
Robert J. Gould, Ph.D., former president and founding chief executive officer of Fulcrum, is appointed as interim CEO as Bryan Stuart departs to pursue other opportunities
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Over $13 Million Bet On This Biotechnology Stock? Check Out These 4 Stocks Insiders Are Buying
↗
December 19, 2022
Although US stocks closed lower on Friday, there were a few notable insider trades.
Via
Benzinga
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 05, 2022
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics to Participate at Upcoming 2022 BofA Securities Biotech SMID Cap Conference
December 01, 2022
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics® Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 11, 2022
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Announces Recent Business Highlights and Third Quarter 2022 Financial Results
November 08, 2022
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Appoints Chief Medical Officer and Chief Scientific Officer
November 07, 2022
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
Fulcrum Therapeutics Earnings Preview
↗
November 07, 2022
Fulcrum Therapeutics (NASDAQ:FULC) is set to give its latest quarterly earnings report on Tuesday, 2022-11-08. Here's what investors need to know before the announcement. Analysts estimate that Fulcrum...
Via
Benzinga
Fulcrum Therapeutics® to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Tuesday, November 8, 2022 at 8:00 a.m. ET
November 02, 2022
From
Fulcrum Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
